trending Market Intelligence /marketintelligence/en/news-insights/trending/cPb3hb957DzSHZrqdSRUwQ2 content esgSubNav
In This List

Eli Lilly: price it was paid for Humalog insulin fell 8.1% over past 5 years

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


Eli Lilly: price it was paid for Humalog insulin fell 8.1% over past 5 years

Eli Lilly and Co. said the price it was paid for its Humalog insulin dropped 8.1% over the last five years after accounting for rebates and discounts, The Wall Street Journal reported March 24, citing information from the company.

The Indianapolis-based company said the net price for the widely-used insulin drug — the price after discounts and rebates — fell to an average of $135 a patient a month in 2018 from $147 in 2014, according to the report. Meanwhile, the product’s average list price rose 51.9% to $594 per patient monthly, the Journal reported.

Drugmakers like Lilly are facing scrutiny in the U.S. Congress over big increases in insulin drug prices.